German-founded Kaia Health has raised $27 million in Series B funding to double down on its original therapy for musculoskeletal (MSK) conditions and expand to treat COPD, a cluster of lung conditions. The round was led by Optum Ventures, Idinvest and capital300, plus participation from Balderton Capital, Heartcore Capital and Symphony Ventures.
The therapy combines exercises with educational and psychological support to help users manage chronic pain and improve their conditions. The app uses 2D motion tracking, which enables users to get real-time feedback on physical performance using their smartphone’s camera. In a press release, the company says it is also working toward a 3D musculoskeletal model.
Now headquartered in New York City, the health tech company has raised $50 million since its founding in 2016, including two rounds last year: $8 million in September and $10 million in January.
“Similar to the explosion we’ve seen in doctor to patient telehealth, the healthcare challenges arising from COVID has also highlighted the need for new care delivery models,” said Kaia Founder and President Konstantin Mehl. “We believe we are on the precipice of moving our solutions from the early adopter set to mass market, and this funding will help us aggressively expand the reach and impact of our platform.”